What Are The Key Clinical Indications And Contraindications To Evaluate Before Performing Er:yag Laser Skin Resurfacing? Essential Safety Checklist For Clinicians

Before performing Er:YAG laser skin resurfacing, confirm both the treatment indication and the patient’s ability to heal safely. Er:YAG resurfacing is primarily used for superficial dyschromia, coarse texture, photoaging, perioral or periorbital rhytids, and acne or traumatic scars. Treatment should be deferred or avoided when active infection, impaired immunity, recent systemic isotretinoin use, active malignancy, active melasma, or other factors could impair re-epithelialization or produce unacceptable scarring or pigmentary change.

The key decision is not simply whether Er:YAG can improve the target lesion. It is whether the expected benefit justifies the patient’s wound-healing, scarring, pigmentary, ocular, and compliance risks.

Which Clinical Problems Are Appropriate Indications?

Superficial photoaging and texture change

Er:YAG resurfacing is well suited to superficial photoaging, uneven or coarse surface texture, and superficial dyschromia. Its ablative action removes controlled layers of epidermis and, depending on settings, superficial dermis to stimulate remodeling.

Fine and moderate rhytids

Common targets include perioral and periorbital rhytids, particularly when wrinkles are related to photodamage and superficial textural change.

Treatment depth and energy should match wrinkle severity. Deeper or more established wrinkles may require alternative or combined approaches rather than simply increasing Er:YAG treatment intensity.

Acne and traumatic scarring

Er:YAG may be considered for atrophic acne scars and selected traumatic scars, especially when the principal problem is superficial irregularity.

Deep, sharply defined scars may respond incompletely to resurfacing alone. Scar depth, tethering, skin type, and the risk of post-inflammatory hyperpigmentation should influence the treatment plan.

Other selected ablative targets

Ablative resurfacing may also be used in selected protocols for scar revision and certain superficial actinic or benign epidermal lesions. These uses require confirmation that the lesion is appropriately diagnosed and that suspicious or malignant lesions are not being treated without proper evaluation.

Which Findings Are Contraindications?

Active infection in the treatment field

Active bacterial, viral, or fungal infection is an absolute contraindication until it has resolved.

This includes active herpes simplex lesions. A history of herpes simplex is not necessarily a reason to exclude treatment, but it generally requires antiviral prophylaxis and careful monitoring.

Recent oral isotretinoin therapy

The primary reference identifies oral isotretinoin use within the preceding 12 months as an absolute contraindication. The appropriate interval may vary with treatment depth, device labeling, and current specialist guidance; deeper full-field procedures may warrant a longer delay than superficial or fractional treatments.

The underlying concern is impaired sebaceous and adnexal function, which may compromise re-epithelialization and healing.

Active cancer or suspicious lesions

Do not resurface over active skin cancer or an undiagnosed suspicious lesion. Lesions requiring diagnosis should be assessed and managed before cosmetic resurfacing.

Active melasma

Active melasma is an absolute contraindication in the primary reference because resurfacing can aggravate pigment instability and produce a poor cosmetic outcome.

Patients with a history of melasma or post-inflammatory dyschromia require particularly careful counseling, pigment control, and conservative treatment selection.

Impaired immune function

Patients with significant immune impairment may have increased risks of infection, delayed healing, and abnormal inflammation. The cause and severity of the impairment should be evaluated before considering treatment.

Inability to follow aftercare

Even when not listed as a device-specific absolute contraindication, inability or unwillingness to follow wound care and sun-protection instructions is a practical reason to defer treatment. Healing depends on adherence to cleansing, medication, infection precautions, and strict ultraviolet avoidance.

Which Patients Require Modification or Extra Caution?

Personal or family history of keloids

A history of keloid or hypertrophic scar formation increases the risk of an abnormal scar response.

This is generally treated as a major relative contraindication requiring detailed counseling, conservative parameters, and—in selected cases—a small test area rather than immediate full-field treatment.

Prior radiation, deep burns, or destructive procedures

Prior radiation therapy, deep burns, deep peels, dermabrasion, or aggressive laser treatment may have damaged the appendageal structures needed for epidermal regeneration.

Treatment areas with reduced or absent hair follicles and sebaceous glands may heal poorly. These regions warrant avoidance or highly conservative treatment, depending on the extent of structural damage.

Collagen vascular disease

Active or clinically significant collagen vascular disease, including conditions such as scleroderma or systemic lupus erythematosus, may impair healing or alter the inflammatory response.

The disease status, medications, treatment area, and specialist input should be reviewed before proceeding.

Darker skin phototypes and pigmentary history

Patients with darker Fitzpatrick skin types or a history of post-inflammatory hyperpigmentation or dyschromia have a greater risk of persistent pigment alteration after ablative treatment.

Er:YAG generally produces less thermal injury than CO₂ resurfacing, but it is not pigment-risk free. Superficial, fractional, or staged treatment may be preferable to aggressive full-field resurfacing.

Eyelid laxity and prior eyelid surgery

Pronounced lower eyelid laxity or previous blepharoplasty increases the risk of postoperative ectropion, particularly during periorbital treatment.

Assess lid tone, snap-back, scleral show, and relevant surgical history. If laxity is significant, modify the plan, avoid aggressive periorbital treatment, or obtain appropriate specialist evaluation.

Active acne or inflammatory dermatoses

Active acne and inflammatory or koebnerizing disorders may complicate healing and increase the risk of worsening inflammation or pigmentary change.

Treatment is usually best postponed until the condition is controlled, especially when the planned resurfacing is broad or relatively deep.

Smoking, diabetes, and other healing risks

Smoking and diabetes may impair microvascular function and wound healing. These factors should be incorporated into the risk assessment rather than treated as isolated checklist items.

The more extensive the treatment, the more important these systemic risks become.

What Should the Pre-Treatment Evaluation Establish?

Confirm the diagnosis and treatment goal

Document the specific problem being treated: dyschromia, texture, rhytids, photoaging, or scarring. Confirm that the expected improvement is realistic for the lesion’s depth and the selected Er:YAG technique.

Review medications and prior procedures

Ask specifically about:

Oral isotretinoin and other retinoids
Medications or conditions that impair immunity or healing
Prior radiation, burns, deep peels, dermabrasion, or laser treatments
Prior electrolysis or other procedures that may destroy follicles
Current or recurrent herpes simplex
Previous abnormal scarring

The relevant risk is not only the medication itself, but also how it affects epidermal regeneration, inflammation, infection risk, and collagen remodeling.

Examine the treatment area

Look for infection, suspicious lesions, active inflammation, melasma, severe pigment instability, scarring, thin or fibrotic skin, and compromised adnexal structures.

For periorbital treatment, include a focused eyelid and lower-lid laxity assessment.

Assess phototype and sun exposure

Record Fitzpatrick skin type and history of hyperpigmentation or hypopigmentation. Determine whether the patient can comply with strict sun avoidance during healing and the subsequent period of pigment instability.

Evaluate expectations and adherence

Patients should understand likely improvement, limitations, downtime, pigment risk, infection precautions, and the possibility of staged treatment. Unrealistic expectations or poor expected compliance should prompt postponement rather than escalation of treatment intensity.

Understanding the Trade-offs

More aggressive treatment is not automatically better

Increasing depth or energy may improve more pronounced textural defects, but it also increases downtime and the risks of infection, delayed healing, scarring, pigmentary change, and eyelid malposition.

A staged or fractional approach may provide a safer balance when risk factors are present.

Lower pigment risk does not mean no pigment risk

Er:YAG has less residual thermal injury than some other ablative lasers, which may reduce—but does not eliminate—the risk of post-inflammatory hyperpigmentation.

Patient selection, conservative settings, sun protection, and appropriate pigment management remain essential.

A relative contraindication is not a routine indication

A patient with a relative contraindication should not automatically be treated using standard parameters. The options may include postponement, medical optimization, a test spot, reduced treatment depth, fractional treatment, or selection of a non-ablative alternative.

Test spots have limited but useful value

A small test area can help assess healing and pigment response in selected higher-risk patients. It cannot eliminate risk or reliably predict complications across the entire treatment field.

How to Apply This to Your Project

Use a structured screening process before scheduling treatment, and match the technique to both the indication and the patient’s risk profile.

If your primary focus is superficial photoaging, texture, or fine rhytids: Confirm that the abnormality is superficial and use the least aggressive Er:YAG protocol likely to achieve the intended improvement.
If your primary focus is acne or traumatic scarring: Assess scar depth, tethering, skin type, and whether resurfacing alone can address the defect before selecting treatment.
If your primary focus is patient safety: Defer treatment for active infection, recent oral isotretinoin exposure, active melasma, suspicious lesions, significant immune impairment, or inadequate aftercare commitment.
If your primary focus is treating a higher-risk patient: Consider conservative or fractional treatment, test spots, pigment precautions, antiviral prophylaxis when indicated, and specialist input for scarring, collagen disease, radiation injury, or eyelid laxity.

A sound Er:YAG decision balances the correct clinical indication with the patient’s capacity for predictable healing and aftercare.

Summary Table:

Indications	Contraindications	Relative Contraindications
Superficial photoaging and texture change	Active infection in treatment field	Personal/family history of keloids
Fine/moderate rhytids (perioral, periorbital)	Recent oral isotretinoin (within 12 months)	Prior radiation, deep burns, or destructive procedures
Atrophic acne scars and selected traumatic scars	Active skin cancer or suspicious lesions	Collagen vascular disease
Selected scar revision and superficial actinic lesions	Active melasma	Darker skin types or pigmentary history
	Significant immune impairment	Eyelid laxity or prior eyelid surgery
	Inability to follow aftercare	Active acne or inflammatory dermatoses
		Smoking, diabetes, or healing risks

Ensure safe and effective Er:YAG treatments with expert guidance. At BELIS, we provide professional-grade laser systems and comprehensive training for clinics and premium salons. Our portfolio includes advanced Er:YAG, Diode, Alexandrite, CO2 Fractional, and more – covering every aesthetic category. Contact us today to learn how our technology and support can enhance your practice and patient outcomes. Get in touch with our specialists.